China’s biotech rise is fueled by its 'first to file' patent system. Companies feed newly published patents into computers to design trivially different but functionally identical molecules, effectively creating a 'shadow generic industry' that undermines IP.

Corporate financials require maker-checker systems, audit trails, and severe penalties for fraud. Scientific research data often lacks these controls, with no audit trails or meaningful penalties for errors. This disparity suggests we should apply at least as much skepticism to academic papers as to financial reports.

As AI and automation become central to drug discovery, the physical layout and infrastructure of a lab are no longer just a facility. They are a core competitive advantage, an "experiment upon themselves" that companies actively protect as valuable IP to prevent replication by rivals.

A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.

The US biotech industry is divided on collaborating with Chinese firms. A significant group feels trapped in a prisoner's dilemma: they would prefer if everyone stopped working with Chinese companies, but feel forced to engage because if their competitors do, they'll be at a significant disadvantage by opting out.

Biotech companies are incentivized to own the entire intellectual property for a drug, from delivery to molecule. This leads to endless litigation and siloed innovation, preventing the combination of "best-in-class" components from different companies and ultimately slowing progress for patients.

Despite rising in global rankings, Chinese academia faces a serious credibility issue. In 2024, Chinese-authored papers saw around 3,000 retractions, compared to just 177 for U.S. authors. This is fueled by a business model of 'paper mills' that create fake academic studies.

US officials and AI labs allege Chinese firms are engaged in industrial-scale IP theft. They reportedly use fraudulent accounts to extract capabilities from US models like Claude to train their own, creating a facade of domestic innovation.

Biotech firms are beginning to selectively disclose clinical data, citing the need to protect R&D from fast-following competitors, particularly from China. This forces investors into a difficult position: either trust management without full transparency or discount the company's value due to the opacity.